Dystonia

Clinical Snapshot

Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both.^[1] Dystonic movements are typically patterned and twisting, sometimes tremulous, and it is the sustained twisted posture itself — not simply "abnormal movement" in general — that is the key to recognizing dystonia at the bedside.^[2] Movements are classically absent at rest, triggered or worsened by voluntary action, often somewhat better earlier in the day, and frequently eased by a sensory trick (geste antagoniste) — a light touch to the affected body part that transiently interrupts the abnormal muscle activity.^[2]

Current international consensus classifies dystonia along two axes.^[1] Axis I — clinical characteristics covers age at onset, body distribution, temporal pattern, and associated features. By distribution: focal dystonia affects a single body region — cervical dystonia (the neck), blepharospasm (the eyelids), oromandibular dystonia (the jaw), spasmodic dysphonia (the vocal cords), or a task-specific limb dystonia such as writer's cramp; segmental dystonia affects two or more contiguous regions; multifocal affects two or more non-contiguous regions; generalized dystonia affects the trunk plus at least two other regions; and hemidystonia affects one side of the body only, a pattern that should specifically prompt brain imaging for a structural secondary cause.^[2]^[1] Axis II — etiology spans nervous system pathology and inheritance (inherited, acquired, or idiopathic), with acquired causes including drug exposure, perinatal injury, infection, structural lesions, toxins, vascular disease, and trauma.^[1]^[2]

Onset pattern tracks with etiology in a genuinely useful way at the bedside: dystonia beginning in adulthood is usually primary and tends to stay focal, while dystonia beginning in childhood is usually secondary and is more likely to be — or become — generalized.^[2]

This one chapter title covers three genuinely distinct clinical entities that share only a name and a final common movement phenotype, but demand different — sometimes opposite — pharmacist action: the acute dystonic reaction, a drug-induced emergency unfolding over hours to days that anticholinergics resolve rapidly; chronic primary/secondary dystonia (cervical dystonia, blepharospasm, writer's cramp, and generalized forms), managed with botulinum toxin and oral agents over years; and tardive dystonia, a late, often-persistent complication of chronic dopamine-receptor-blocking drug exposure that anticholinergics do not treat and may actually worsen. Confusing the management of any one of these for another is the single most consequential error a pharmacist can make with this condition.

Recognize the Condition

Chronic focal dystonia — the presentations pharmacists see most often

Focal dystonia by body region

Cervical dystonia (spasmodic torticollis)

The most familiar focal dystonia in adult neurology practice: involuntary, sustained or intermittent contraction of neck muscles producing an abnormal head/neck posture — rotation (torticollis), lateral tilt (laterocollis), backward extension (retrocollis), forward flexion (antecollis), or, most often, a combination. Neck pain and a dystonic head tremor are common associated features. A sensory trick — often a light touch to the chin or jaw — transiently corrects the posture in many patients and is itself a useful diagnostic clue.^[2]

Blepharospasm

Involuntary, bilateral, forceful eyelid closure that can range from frequent excessive blinking to functional blindness during a spasm, despite structurally normal eyes. Bright light, wind, reading, and fatigue commonly provoke it.^[2]

Writer's cramp and other task-specific limb dystonia

Dystonic posturing that appears only during one specific, learned motor skill — classically handwriting, but also playing a musical instrument or another occupational task — while the same limb moves normally for other activities. This task-specificity is itself diagnostic.^[2]

Oromandibular dystonia and spasmodic dysphonia

Involuntary jaw opening/closing or deviation (oromandibular), or a strained, strangled, or breathy voice from laryngeal muscle spasm (spasmodic dysphonia) — less common than cervical dystonia or blepharospasm but managed on the same treatment principles.^[2]

Acute dystonic reaction — the high-yield, pharmacist-relevant emergency

The acute dystonic reaction is an idiosyncratic, drug-induced movement disorder triggered by any dopamine D2 receptor-blocking drug, arising from the resulting dopaminergic-cholinergic imbalance in the basal ganglia. It is most strongly associated with first-generation (typical) antipsychotics — reported in roughly 10.5% of exposed patients, versus about 2.2% with second-generation (atypical) agents — and is also well documented with the antiemetics metoclopramide (approximately 8.3% in adults) and prochlorperazine (approximately 4%).^[3] Onset is fast: symptoms typically emerge within 96 hours of starting the drug or increasing its dose, and risk is highest in young patients, male patients, those with a prior dystonic reaction, and those with reduced CYP2D6 metabolizer status.^[3]

The presentation is dramatic and genuinely frightening for the patient: oculogyric crisis (a sustained, involuntary upward-and-lateral deviation of the eyes), torticollis, trismus (jaw clenching/lockjaw), blepharospasm, and — the presentation that matters most — laryngospasm/pharyngeal dystonia, which can progress to airway compromise. Patients are typically anxious and in real distress but remain fully alert; this combination of severe involuntary posturing with a clear sensorium in a patient recently started or increased on a dopamine-blocking drug is the pattern to recognize.^[3]

Tardive dystonia — a distinct, late, often-persistent complication

Tardive dystonia is a form of tardive syndrome: a persistent and potentially disabling movement disorder that emerges only after prolonged exposure to antipsychotics or other dopamine-receptor-blocking drugs.^[4] Unlike the acute dystonic reaction, which appears within days of starting or increasing the offending drug and resolves rapidly with an anticholinergic, tardive dystonia develops after months to years of cumulative exposure, can persist — sometimes permanently — even after the causative drug is stopped, and, critically, is not reliably treated with the anticholinergic drugs used for the acute reaction (see Choose Initial Treatment).^[4] Correctly identifying which of these two timelines a patient is on is the single most important diagnostic branch point in this chapter.

Risk Factors

Adult-onset dystonia is usually primary/idiopathic and tends to remain focal; childhood-onset dystonia is usually secondary and is more likely to generalize — age at onset is one of the most useful prognostic clues available at the bedside.^[2]
A family history or a known genetic cause (inherited dystonia) — Axis II of the current classification framework explicitly separates inherited, acquired, and idiopathic dystonia, and early-onset generalized dystonia in particular should prompt genetic evaluation.^[1]
Any dopamine D2 receptor-blocking drug — the largest modifiable risk factor in this entire chapter. First-generation antipsychotics carry the highest acute dystonic reaction risk (approximately 10.5%), followed by metoclopramide (approximately 8.3%) and prochlorperazine (approximately 4%); second-generation antipsychotics carry a lower but genuinely non-zero risk (approximately 2.2%).^[3]
Male sex, younger age, a prior acute dystonic reaction, and reduced CYP2D6 metabolizer status all independently raise acute dystonic reaction risk.^[3]
Cumulative, prolonged exposure to a dopamine-receptor-blocking drug — the specific risk driver for tardive dystonia, distinct from the acute reaction's dose-change trigger.^[4]
A structural brain lesion, perinatal injury, prior stroke, infection, or toxin exposure — recognized causes of secondary dystonia, and specifically the reason hemidystonia (one side of the body only) warrants brain imaging.^[2]^[1]
An underlying degenerative or genetic neurologic disease in which dystonia is one feature among several — evaluate for additional neurologic features rather than treating the dystonia in isolation.^[1]

Red Flags & Refer

Any of the following changes the plan from routine assessment to urgent escalation:

Any stridor, marked dysphonia, dyspnea, or difficulty handling secretions in a patient with a suspected acute dystonic reaction — laryngeal/pharyngeal dystonia is a true, airway-threatening emergency and takes priority over every other step; treat it as impending airway obstruction until proven otherwise and arrange emergency care in parallel with giving an anticholinergic, never instead of it.^[3]
Any acute dystonic reaction at all warrants prompt attention — delay in recognition is itself a source of harm, and case reports specifically describe acute dystonic reactions being initially misdiagnosed as a seizure, meningitis, tetanus, or an unclear brain process before the correct drug history was identified.^[3]
A movement presentation that looks bizarre, inconsistent, or emotionally reactive should not be assumed psychiatric or "functional" without a careful history and examination — dystonia (and the genuine distress of an acute dystonic reaction) is itself frequently misread as hysterical or psychogenic in origin, while true psychogenic dystonia is uncommon and recognized as "an extremely difficult diagnosis to make" even by specialists.^[5]
New hemidystonia (one side of the body only) — this pattern specifically suggests a structural secondary cause and needs brain imaging and neurology referral rather than routine focal-dystonia management.^[2]
Any generalized dystonia presenting for the first time in a child needs a full secondary-cause workup, since childhood-onset dystonia is usually secondary and prone to generalize, unlike adult-onset disease.^[2]
New or worsening depression, suicidal ideation, or a marked mood change in a patient started on tetrabenazine (or another VMAT2 inhibitor) for tardive dystonia — this is a genuine, labelled safety signal, not simply "the underlying condition," and needs prompt reassessment.^[6]

The pharmacist's role in the acute dystonic reaction specifically is rapid recognition, plus either treating on the spot with an available anticholinergic (see Choose Initial Treatment) or escalating immediately to emergency care — not watchful waiting.

Assessment & Diagnosis

Dystonia is a clinical diagnosis

There is no laboratory test or single imaging study that confirms dystonia; the diagnosis rests on recognizing the phenomenology described in Recognize the Condition — sustained or intermittent contractions producing a patterned, often twisting posture, triggered or worsened by action, and often eased by a sensory trick.^[2]^[1]

The first and most urgent diagnostic branch: timeline and drug exposure

Before classifying a patient's dystonia by body distribution, establish two facts: (1) has any dopamine-receptor-blocking drug been started or increased in the past hours to days, and (2) has the patient had prolonged (months-to-years) cumulative exposure to such a drug? These two questions separate the acute dystonic reaction and tardive dystonia from primary/idiopathic chronic dystonia, and each of the three requires different management (see Clinical Decision Algorithm).

Differential diagnosis of the acute presentation

Acute dystonic reactions are genuinely easy to misdiagnose, particularly when a medication history is not volunteered or not specifically asked about. Reports describe patients initially diagnosed with a seizure, meningitis, tetanus, or an unclear brain process before the correct diagnosis was reached.^[3] A directed medication history — any new antipsychotic, antiemetic, or other dopamine-blocking drug — is the single most useful diagnostic step, and response to an anticholinergic trial is itself both diagnostic and therapeutic (see Choose Initial Treatment).

Psychogenic (functional) dystonia — a genuine and difficult mimic

Dystonia, and the distress that accompanies an acute dystonic reaction in particular, is often misread as hysterical or psychiatric in origin — while true psychogenic dystonia is itself uncommon and genuinely hard to diagnose.^[5] A Canadian case series of 18 patients found the clinical characteristics of psychogenic dystonia to be inconsistent or incongruous with established forms of organic dystonia: onset was abrupt with rapid progression, often to fixed dystonic postures; leg involvement was common despite adult-life onset, atypical for organic dystonia; paroxysmal worsening occurred in the majority; and pain was a prominent feature in most patients.^[5] Do not use a "looks psychiatric" impression alone to withhold or delay treatment from a patient having a genuine acute dystonic reaction.

Investigations

Investigations are targeted, not routine, and exist mainly to identify a secondary cause or exclude a mimic rather than to "confirm" dystonia itself.

Brain MRI — indicated for hemidystonia, any focal neurologic deficit, an atypical or rapidly progressive course, or childhood-onset generalized dystonia without a clear cause, to look for a structural secondary lesion.^[2]
Genetic testing — considered for early-onset generalized dystonia, particularly with a family history, consistent with the inherited/acquired/idiopathic distinction built into the current classification framework.^[1]
Medication and exposure history — the single most important "investigation" in this entire chapter: a careful, specific review of every dopamine-receptor-blocking drug (antipsychotics, metoclopramide, prochlorperazine) and its timing relative to symptom onset.^[3]
Creatine kinase and renal function are reasonable to check in any patient with severe, diffuse, or prolonged dystonic contraction, given the general risk of muscle injury from sustained involuntary contraction.
Routine bloodwork, EEG, and lumbar puncture are not needed to diagnose a typical acute dystonic reaction or typical focal dystonia, and reflexively pursuing them can delay the anticholinergic trial that both treats the acute reaction and helps confirm the diagnosis.

Treatment Targets

Recognize and treat the acute dystonic reaction rapidly — anticholinergics work within minutes, and speed genuinely changes both how much the patient suffers and how much unnecessary escalation (unneeded testing, misdiagnosis-driven delay) occurs.
Protect the airway proactively whenever laryngeal or pharyngeal involvement is possible, rather than waiting for overt respiratory distress.
Correctly distinguish the acute dystonic reaction from tardive dystonia before choosing a drug — the two conditions require different, and in one respect opposite, pharmacotherapy.
Provide effective, sustained symptom control for chronic focal dystonia (cervical dystonia, blepharospasm, writer's cramp) with botulinum toxin as first-line therapy, redosed on an appropriate interval.
Reserve oral agents (anticholinergics, baclofen, benzodiazepines) for generalized/segmental dystonia or for focal disease inadequately controlled by botulinum toxin, titrating to the lowest effective dose given their genuine adverse-effect burden.
For tardive dystonia: use a VMAT2 inhibitor, not an anticholinergic, and involve the prescriber in reassessing the causative antipsychotic.
Prevent recurrence — of the acute reaction with an oral anticholinergic taper, and of tardive dystonia by using the lowest effective antipsychotic dose and monitoring for early signs.
Support the genuine quality-of-life goals (return to work, driving, reading, social functioning) that chronic focal dystonia disrupts, alongside movement control itself.

Choose Initial Treatment

Direct treatment rule

Match the drug to the timeline — this is the decision that matters most

Acute dystonic reaction (hours to days after starting/increasing a dopamine-blocking drug) an IV/IM anticholinergic — benztropine or diphenhydramine — is first-line and works within minutes. Chronic focal dystonia (cervical dystonia, blepharospasm, writer's cramp) with no drug-induced trigger botulinum toxin injection is first-line. Tardive dystonia (a late complication of months-to-years of antipsychotic exposure) anticholinergics are not the answer here and may worsen the syndrome^[4] — a VMAT2 inhibitor is first-line instead. Confirming which of these three clinical pictures is in front of you, using the history in Assessment & Diagnosis, must happen before reaching for any drug.

Acute dystonic reaction — treat now, then prevent recurrence

First step, every time assess the airway before anything else — stridor, marked dysphonia, dyspnea, or difficulty handling secretions means laryngeal/pharyngeal dystonia, and emergency airway support must be arranged in parallel with (not instead of) giving the anticholinergic.^[3] No airway compromise give benztropine 1-2 mg IV or IM, or diphenhydramine 50 mg IV or IM (pediatric: 1 mg/kg up to 50 mg); both are equally effective first-line choices, and symptoms usually improve or resolve dramatically within 10-30 minutes.^[3] May repeat the dose once at 15-30 minutes if the response is inadequate.^[3] After acute resolution start an oral anticholinergic taper — benztropine 1-2 mg PO twice daily for 2-3 days, or diphenhydramine 25 mg PO four times daily for 24-72 hours — since dystonia commonly recurs once the parenteral dose wears off, particularly if the causative drug is continued.^[3] Always discuss discontinuing or switching the causative agent with the prescriber where clinically feasible; if it must be continued (for example, an antipsychotic that is otherwise working well psychiatrically), a scheduled prophylactic oral anticholinergic is a reasonable next discussion rather than repeated emergency visits.

Chronic focal and segmental dystonia — botulinum toxin first-line

Cervical dystonia, blepharospasm, writer's cramp, and most other focal dystonias botulinum toxin injection into the affected muscles is first-line therapy, ahead of oral agents, for essentially all patients able to access it.^[7] Injections are individualized — dose is not fixed but titrated to each patient's specific pattern of muscle involvement and response — and re-treatment should not be given sooner than 12 weeks from the prior injection, both to match the interval used in the placebo-controlled cervical dystonia trials and to limit the risk of neutralizing-antibody formation with more frequent dosing.^[7] For cervical dystonia specifically, published dosing for abobotulinumtoxinA is an initial 500 U divided intramuscularly among the affected muscles, with re-treatment doses of 250-1,000 U at intervals of no less than 12 weeks; onabotulinumtoxinA doses across controlled cervical dystonia trials have ranged from as low as 17 U to as high as 240 U, again individualized rather than fixed.^[7]^[8] Products are not unit-interchangeable onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, and letibotulinumtoxinA each have their own dosing scale — confirm exactly which product a patient has been receiving before assuming a dose translates from one to another.

Inadequate response to botulinum toxin reassess muscle selection and injection technique (EMG or ultrasound guidance can help target deep or hard-to-localize muscles) before assuming treatment failure, then consider adding an oral agent (trihexyphenidyl or baclofen) or referral for the generalized/refractory-disease pathway below.

Generalized or refractory dystonia — oral agents, then specialist referral

Oral pharmacotherapy a trial of an anticholinergic (trihexyphenidyl, titrated slowly from a low starting dose — children and young adults typically tolerate substantially higher doses than older adults), baclofen, or a benzodiazepine (as an adjunct, not monotherapy) is reasonable for generalized or segmental dystonia, or for focal dystonia inadequately controlled by botulinum toxin.^[2] These oral agents carry a genuine anticholinergic and sedative burden, particularly in older adults, and should be titrated to the lowest effective dose. Refractory to oral therapy refer to a movement disorders specialist for deep brain stimulation candidacy assessment — outcomes vary widely by underlying cause, with the best results generally seen in primary/inherited dystonia without structural brain change and more modest results in dystonia secondary to a fixed structural brain injury.^[9]

Tardive dystonia — a different drug, and a genuinely important warning

Do not use anticholinergics they are appropriate for drug-induced parkinsonism and for the acute dystonic reaction, but are not recommended for tardive syndromes and may even worsen them.^[4] First-line in Canada tetrabenazine, a VMAT2 inhibitor Health Canada has approved for hyperkinetic movement disorders including tardive dyskinesia; movement disorder specialists extend the same drug to tardive dystonia given the shared underlying mechanism and drug class.^[6] Start low (12.5 mg PO twice or three times daily) and titrate slowly — by no more than 12.5 mg/day at weekly intervals — to the lowest effective, tolerated dose; most patients land at a maximal tolerated dose of about 25 mg three times daily, though the product monograph describes rare cases needing up to 200 mg/day.^[6] Not available in Canada valbenazine and deutetrabenazine are VMAT2 inhibitors approved specifically for tardive dyskinesia, with generally favourable comparative safety data, but neither is Health Canada-approved or stocked in Canadian pharmacies — a pharmacist may still encounter them on a cross-border or transferred prescription and should recognize the drug class rather than assume an error.^[10] Alongside drug therapy involve the prescriber in reassessing the causative antipsychotic — a dose reduction or a switch to a lower-risk agent, where psychiatrically safe to do so — since ongoing exposure to the causative drug class works against recovery.

Non-Pharmacologic Treatment

Sensory tricks (geste antagoniste) — many patients with cervical dystonia or other focal dystonias can find their own light touch or posture (for example, a touch to the chin or cheek) that transiently reduces the abnormal posture; encourage patients to find and use their own trick as a genuine, no-cost adjunct to drug therapy, not a curiosity.^[2]
Physical and occupational therapy — stretching, postural retraining, and task modification (for example, adaptive writing tools for writer's cramp) support drug therapy, particularly between botulinum toxin cycles.
Deep brain stimulation for generalized or severely disabling dystonia refractory to oral therapy — a genuine, recognized option, with outcomes that vary meaningfully by cause: generally better in primary/inherited dystonia without structural brain change, more modest in dystonia secondary to a fixed structural injury. Cervical dystonia and tardive dystonia are also recognized candidate indications for carefully selected patients.^[9] This decision is made by a movement disorders specialist and neurosurgical team, not initiated in general practice.^[9]
Intrathecal baclofen — a pump-delivered option specifically for severe generalized dystonia, particularly of secondary/structural cause, when oral baclofen is inadequate or not tolerated at the doses needed.
Avoid abrupt discontinuation of any chronic anticholinergic, baclofen, or benzodiazepine regimen — taper deliberately to avoid withdrawal effects (including, for baclofen, a withdrawal syndrome that can include seizures).
For the acute dystonic reaction specifically: reassure the patient throughout — they are fully alert and often frightened by involuntary movements they cannot control, and clearly communicating that this is a known, treatable drug effect (not a seizure or a psychiatric event) is itself part of the treatment.
Keep a clear, written record of exactly which drug caused an acute dystonic reaction, in the patient's allergy/intolerance record, to prevent inadvertent re-exposure — a genuinely preventable repeat event.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Benztropine Preferred	Acute dystonic reaction — first-line emergency treatment, then oral taper	1-2 mg IV/IM, may repeat once at 15-30 min; then 1-2 mg PO twice daily for 2-3 days as a taper	Anticholinergic effects: dry mouth, blurred vision, urinary retention, confusion (especially in older adults)	Not for tardive dystonia — anticholinergics do not treat tardive syndromes and may worsen them
Diphenhydramine Preferred	Acute dystonic reaction — first-line emergency treatment, then oral taper	50 mg IV/IM (pediatric 1 mg/kg up to 50 mg), may repeat once at 15-30 min; then 25 mg PO four times daily for 24-72 hours as a taper	Sedation, anticholinergic effects, paradoxical excitation in children	Equally effective to benztropine for the acute reaction; sedation can be useful or unwanted depending on setting
Trihexyphenidyl Alternative	Oral taper after an acute reaction; maintenance therapy for generalized/segmental dystonia	Start low and titrate slowly to effect; children and young adults typically tolerate substantially higher doses than older adults	Anticholinergic burden, cognitive/memory effects (especially in older adults), blurred vision, constipation	High-dose anticholinergic therapy is far better tolerated in children with generalized dystonia than in adults
Baclofen Alternative	Generalized/segmental dystonia — oral, or intrathecal for severe secondary disease	Oral: start low, titrate to effect. Intrathecal: specialist-programmed pump	Sedation, weakness, hypotonia; abrupt-withdrawal seizures/rebound spasticity	Never stop abruptly, whether oral or intrathecal — taper deliberately or arrange pump refill proactively
Diazepam Special situation	Adjunct for dystonic tremor, or add-on in generalized dystonia	Individualized, low starting dose, titrate to effect	Sedation, dependence with prolonged use, tolerance	An adjunct alongside other agents, not primary monotherapy, for most dystonia phenotypes
OnabotulinumtoxinA Preferred	First-line for cervical dystonia, blepharospasm, and other focal dystonias	Individualized; cervical dystonia doses in controlled trials have ranged 17-240 U; re-inject no sooner than 12 weeks	Dysphagia, neck weakness, ptosis (with periocular injection), injection-site pain/bruising	Not unit-interchangeable with other botulinum toxin products — confirm the specific product a patient has received
AbobotulinumtoxinA Preferred	First-line alternative for cervical dystonia	Initial 500 U divided IM; re-treatment 250-1,000 U at intervals of no less than 12 weeks	Same class effects: dysphagia, neck weakness, injection-site pain	Same non-interchangeability caution as onabotulinumtoxinA
IncobotulinumtoxinA Alternative	Alternative botulinum toxin product for cervical dystonia/blepharospasm	Individualized per product monograph	Same class effects as other botulinum toxin products	Free of complexing proteins — a consideration when switching products for suspected secondary non-response
PrabotulinumtoxinA Alternative	Alternative botulinum toxin product for cervical dystonia	Individualized per product monograph	Same class effects as other botulinum toxin products	Confirm product-specific dosing before switching from another botulinum toxin brand
LetibotulinumtoxinA Alternative	Alternative botulinum toxin product for cervical dystonia	Individualized per product monograph	Same class effects as other botulinum toxin products	Newer to the Canadian market — confirm local prescriber familiarity and product-specific dosing
Tetrabenazine Preferred	Tardive dystonia — Health Canada-approved VMAT2 inhibitor	Start 12.5 mg PO twice or three times daily; titrate by up to 12.5 mg/day at weekly intervals; usual maximal tolerated dose about 25 mg three times daily	Sedation (most common dose-limiting effect), depression/suicidality, akathisia, parkinsonism, QT prolongation	Contraindicated in hepatic impairment, active suicidality/untreated depression, and with MAOIs or reserpine
Valbenazine Special situation	Tardive dystonia/dyskinesia — FDA-approved VMAT2 inhibitor	Not available in Canada; U.S. labelling uses 40-80 mg PO once daily	Sedation, akathisia, dose-dependent QT prolongation	Recognize the class, but it cannot be dispensed in Canada — occasionally seen on a cross-border or transferred prescription
Deutetrabenazine Special situation	Tardive dystonia/dyskinesia — FDA-approved VMAT2 inhibitor	Not available in Canada; dosed twice daily in U.S. labelling given its longer, more stable exposure profile	Sedation, akathisia, dose-dependent QT prolongation	Same recognition-only role in Canadian practice as valbenazine
Anticholinergics (as a class) in tardive dystonia Avoid	Tardive dystonia/dyskinesia	Not recommended	May worsen tardive symptoms rather than improve them	The single most important contrast in this chapter: first-line for the acute reaction, but avoided in its tardive look-alike

Special Populations

Children

Children tolerate high-dose oral anticholinergic therapy (trihexyphenidyl) for generalized dystonia substantially better than adults, making it a genuinely useful option in this population where adults would be limited by cognitive and anticholinergic side effects.^[2] Childhood-onset dystonia is more often secondary and prone to generalize, so investigate for an underlying cause more readily than in an adult with new focal dystonia.^[2] For acute dystonic reactions, dose diphenhydramine at 1 mg/kg IV/IM up to a 50 mg maximum.^[3] Tetrabenazine dosing under 18 years has not been established through adequately controlled trials; limited clinical experience suggests starting at roughly half the adult dose and titrating slowly and carefully according to tolerance and individual response.^[6]

Older adults

Anticholinergic drugs (benztropine, diphenhydramine, trihexyphenidyl) carry a disproportionate burden in older adults — confusion, falls, constipation, urinary retention, and a well-recognized contribution to anticholinergic cognitive load — so use the lowest effective dose and taper promptly once the acute indication has resolved. Tetrabenazine's pharmacokinetics have not been systematically evaluated in patients over 65; clinical experience favours a reduced initial and maintenance dose, since parkinsonian-like adverse effects are relatively common in this group and can be dose-limiting.^[6]

Pregnancy and breastfeeding

Tetrabenazine is not recommended during pregnancy or in patients of childbearing potential not using contraception, based on animal reproductive toxicity findings and the absence of adequate human safety data; it should also be avoided during breastfeeding, since it is excreted in milk.^[6] Botulinum toxin use in pregnancy is generally reserved for situations where the benefit clearly outweighs any theoretical risk, decided case by case with the prescriber. Discuss anticholinergic use in pregnancy or breastfeeding case by case with the prescriber given limited dedicated safety data for this specific indication.

Hepatic impairment

Tetrabenazine is contraindicated in hepatic impairment of any degree — plasma concentrations of its active metabolites rise markedly (peak concentrations 7- to 190-fold higher than in patients with normal liver function in the studied population), and there is no established way to adjust the dose safely for this increased exposure.^[6]

Renal impairment

No dedicated tetrabenazine dose adjustment is described for renal impairment in the Canadian product monograph; use standard clinical judgment and monitor for accumulation of anticholinergic and sedative adverse effects, which can be more pronounced with reduced clearance of other concomitant drugs.^[6]

CYP2D6 poor metabolizers and drug interactions

Tetrabenazine's active metabolites are principally cleared by CYP2D6; poor metabolizers, or patients on a strong CYP2D6 inhibitor (for example, fluoxetine, paroxetine, quinidine, bupropion, or terbinafine), have substantially increased exposure — roughly 3- to 10-fold increases across its two active metabolites with a strong inhibitor on board — and need a lower starting and maintenance dose.^[6] Tetrabenazine is contraindicated with MAOIs (allow at least 14 days between stopping one and starting the other) and with reserpine (allow at least 20 days after stopping reserpine), and should be avoided with other QT-prolonging drugs, including many antipsychotics.^[6] Reduced CYP2D6 metabolizer status is also an independent risk factor for the acute dystonic reaction itself.^[3]

Monitoring & Follow-Up

For the acute dystonic reaction: follow up specifically to confirm the oral anticholinergic taper is being taken and completed, since recurrence once a single parenteral dose wears off is common, particularly if the causative drug is continued.^[3] Document the causative drug clearly in the patient's allergy/intolerance record so it is flagged before any future re-exposure.

For chronic focal dystonia on botulinum toxin: track response and duration of benefit at each visit, since both the interval between injections (no sooner than 12 weeks) and the dose may need individual adjustment over time.^[7] A pattern of shortening benefit or declining response despite dose increases should prompt reassessment for secondary non-response — including neutralizing antibodies — rather than simply escalating the dose further.

For tardive dystonia on tetrabenazine: monitor specifically for new or worsening depression and suicidal ideation at every visit — informing the patient and their caregivers of this risk up front, and instructing them to report concerning changes promptly, is a labelled expectation of therapy, not an optional add-on.^[6] Also monitor for sedation (the most common dose-limiting effect), parkinsonism, akathisia, and orthostatic symptoms, and periodically reassess the need for continued therapy alongside the underlying psychiatric condition and its own medications.^[6]

For any patient on a chronic anticholinergic or baclofen regimen: periodically reassess whether the dose remains the lowest effective one, particularly as patients age into a higher-risk group for anticholinergic burden.

Treatment Failure / Next Step

Acute dystonic reaction not improving within 30 minutes of a first anticholinergic dose: give a second dose (benztropine or diphenhydramine) rather than switching agents or simply waiting longer, and reassess the airway again at each step.^[3]
Recurrent dystonic posturing after apparent resolution of an acute reaction: this usually means the oral taper was not started, was inadequate, or the causative drug was continued unchanged — confirm all three before assuming a new problem.
A presentation that looks like an acute dystonic reaction but does not respond at all to an anticholinergic trial: reconsider the diagnosis — a seizure, a primary psychiatric event, or true psychogenic dystonia are all real alternatives that have been reported to mimic this presentation.^[3]^[5]
Botulinum toxin with declining or absent benefit despite an adequate, individualized dose and correct muscle selection: consider secondary non-response (including neutralizing antibodies), and discuss a change of product (for example, to a formulation without complexing proteins) or of injection technique (EMG/ultrasound guidance) with the treating specialist, rather than simply repeating the same regimen.
Generalized dystonia inadequately controlled despite an adequate trial of oral agents: refer for deep brain stimulation candidacy assessment rather than continuing to escalate oral doses into a burdensome adverse-effect range.^[9]
Tardive dystonia not improving on an adequate tetrabenazine trial: confirm the antipsychotic dose has genuinely been minimized or switched where psychiatrically feasible, reconfirm the diagnosis is tardive dystonia rather than an evolving acute reaction or another movement disorder, and escalate to a movement disorders specialist — do not add an anticholinergic to try to "boost" the response, since this is the specific error most likely to worsen the syndrome.^[4]

Common Errors to Avoid

Treating tardive dystonia with an anticholinergic because "it worked for the last dystonia this patient had" — this is the single most important error in this chapter; anticholinergics are appropriate for the acute reaction and not for tardive syndromes, which they may worsen.^[4]
Missing laryngeal/pharyngeal involvement in an acute dystonic reaction because the patient's limb or neck posturing is the most visually obvious finding — always specifically ask about and assess for stridor, dysphonia, and dyspnea.^[3]
Assuming an acute dystonic reaction is a seizure, a primary psychiatric event, or "attention-seeking" because the presentation looks dramatic and the patient remains fully alert — alertness with severe involuntary posturing is precisely the pattern that should raise, not lower, suspicion for a dystonic reaction.^[3]
Stopping at a single parenteral anticholinergic dose and sending the patient home without an oral taper — recurrence once the parenteral dose wears off is common, especially if the causative drug is continued.^[3]
Reflexively escalating a botulinum toxin dose, or re-injecting sooner than 12 weeks, when response seems inadequate, rather than first reassessing muscle selection/technique or considering secondary non-response.^[7]
Assuming botulinum toxin products are interchangeable unit-for-unit between brands — they are not.
Starting tetrabenazine without asking about a personal history of depression or suicidality, or without setting the expectation of monitoring for this specific, labelled risk.^[6]
Using tetrabenazine in a patient with any degree of hepatic impairment — this is a contraindication, not a relative caution.^[6]
Dismissing a genuinely bizarre-looking movement presentation as purely psychogenic without a careful history and examination — true psychogenic dystonia exists but is uncommon and difficult to diagnose, and organic dystonia (including the acute drug-induced reaction) is far more often the real explanation.^[5]
Forgetting that childhood-onset dystonia is usually secondary and prone to generalize — treating a child's new dystonia exactly like an adult's new focal dystonia risks missing an underlying cause.^[2]

Clinical Decision Algorithm

Algorithm A — First, classify by timeline

New or longstanding sustained muscle contraction, abnormal posture, or repetitive twisting movement

Establish drug exposure history: any dopamine-receptor-blocking drug (antipsychotic, metoclopramide, prochlorperazine) started/increased recently, or taken chronically?^[3]

Onset within hours to days of starting/increasing the drug

Acute dystonic reaction — a time-sensitive drug-induced emergency; go to Algorithm B^[3]

Onset after months to years of cumulative dopamine-blocker exposure

Tardive dystonia — a distinct, often-persistent late complication; do NOT manage like an acute reaction; go to Algorithm C^[4]

No temporal link to a dopamine-blocking drug

Classify by body distribution (focal, segmental, generalized, hemidystonia) and screen for a secondary cause; adult-onset is usually primary and focal, childhood-onset is usually secondary and prone to generalize^[2]

Primary/idiopathic chronic dystonia (e.g., cervical dystonia, blepharospasm, writer's cramp) — go to Algorithm C for ongoing management

Algorithm B — Acute dystonic reaction: treat now, then prevent recurrence

Acute dystonic reaction suspected: oculogyric crisis, torticollis, trismus, blepharospasm, or laryngospasm within hours to days of a dopamine-blocking drug

FIRST, before anything else: assess the airway — stridor, marked dysphonia, dyspnea, or difficulty handling secretions signal laryngeal/pharyngeal dystonia^[3]

Any airway compromise

Treat as an airway emergency: arrange emergency airway support in parallel with giving the anticholinergic — do not wait to see if the drug works before escalating^[3]

No airway compromise (oculogyric crisis, torticollis, trismus, or limb dystonia only)

Give benztropine 1-2 mg IV/IM OR diphenhydramine 50 mg IV/IM (pediatric 1 mg/kg up to 50 mg) without delay^[3]

Expect dramatic improvement within 10-30 minutes; may repeat once at 15-30 minutes if response is inadequate^[3]

Discuss discontinuing or switching the causative drug with the prescriber where feasible

Start an oral anticholinergic taper (benztropine 1-2 mg PO twice daily for 2-3 days, or diphenhydramine 25 mg PO four times daily for 24-72 hours) to prevent recurrence^[3]

Algorithm C — Chronic dystonia: match therapy to distribution and cause

Confirmed chronic dystonia, classified by distribution and etiology

Focal/segmental, primary — cervical dystonia, blepharospasm, writer's cramp

Botulinum toxin injection first-line — individualized dose; re-inject no sooner than 12 weeks^[7]^[8]

Inadequate response: reassess muscle selection/technique (consider EMG/ultrasound guidance) before adding an oral agent or referring onward

Generalized, or focal/segmental disease refractory to botulinum toxin

Trial oral agents: high-dose trihexyphenidyl (especially in children/young adults), baclofen, or a benzodiazepine adjunct^[2]

Refractory to oral therapy: refer to a movement disorders specialist for deep brain stimulation candidacy — outcomes vary widely by underlying cause^[9]

Tardive dystonia — late complication of chronic dopamine-blocker exposure

Do NOT use anticholinergics — not effective for tardive syndromes and may worsen them^[4]

First-line: tetrabenazine (Health Canada-approved VMAT2 inhibitor); valbenazine/deutetrabenazine are FDA-approved alternatives not available in Canada^[6]^[10]

In parallel: work with the prescriber to minimize or switch the causative antipsychotic where psychiatrically feasible

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Acute Dystonic Reaction — Emergency Anticholinergics and Oral Taper

Give the parenteral dose without delay once an airway assessment is complete; follow with an oral taper to prevent recurrence once the causative drug's effect has worn off.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Benztropine	Emergency: 1-2 mg IV or IM Oral taper: 1-2 mg PO twice daily for 2-3 days	Anticholinergic effects: dry mouth, blurred vision, urinary retention, confusion (especially in older adults)	Additive anticholinergic burden with other anticholinergic drugs	May repeat once at 15-30 minutes if response is inadequate; follow with an oral taper to prevent recurrence.
Diphenhydramine	Emergency (adult): 50 mg IV or IM Emergency (pediatric): 1 mg/kg IV or IM, up to 50 mg Oral taper: 25 mg PO four times daily for 24-72 hours	Sedation, anticholinergic effects, paradoxical excitation in children	Additive CNS depression with other sedating drugs	Equally effective to benztropine for the acute reaction; useful when sedation is also desirable.
Trihexyphenidyl	Oral taper/maintenance: Start low, titrate slowly to effect	Anticholinergic burden, cognitive/memory effects (especially in older adults), blurred vision, constipation	Additive anticholinergic burden with other anticholinergic drugs	An oral taper alternative, and the preferred oral maintenance anticholinergic for generalized dystonia given better tolerability in children.

Botulinum Toxin Products — First-Line for Chronic Focal Dystonia

Individualized dosing based on muscle involvement and response; re-treatment no sooner than 12 weeks from the prior injection. Products are not unit-interchangeable — confirm exactly which product a patient has received before assuming a dose translates from one to another.

Drug	Dosage	Adverse effects	Drug interactions	Comments
OnabotulinumtoxinA	Cervical dystonia: Individualized, 17-240 U divided among affected muscles	Dysphagia, neck weakness, ptosis (with periocular injection), injection-site pain/bruising	Additive effect with aminoglycosides or other neuromuscular-blocking drugs	Cervical dystonia doses in controlled trials have ranged 17-240 U, individualized rather than fixed.
AbobotulinumtoxinA	Cervical dystonia, initial: 500 U divided IM Re-treatment: 250-1,000 U, no sooner than 12 weeks	Same class effects as onabotulinumtoxinA	Additive effect with aminoglycosides or other neuromuscular-blocking drugs	Not unit-equivalent to onabotulinumtoxinA — use this product's own dosing scale.
IncobotulinumtoxinA	Cervical dystonia/blepharospasm: Individualized per product monograph	Same class effects as other botulinum toxin products	Additive effect with aminoglycosides or other neuromuscular-blocking drugs	Free of complexing proteins — a consideration when switching products for suspected secondary non-response.
PrabotulinumtoxinA	Cervical dystonia: Individualized per product monograph	Same class effects as other botulinum toxin products	Additive effect with aminoglycosides or other neuromuscular-blocking drugs	Confirm product-specific dosing before switching from another botulinum toxin brand.
LetibotulinumtoxinA	Cervical dystonia: Individualized per product monograph	Same class effects as other botulinum toxin products	Additive effect with aminoglycosides or other neuromuscular-blocking drugs	Newer to the Canadian market — confirm local prescriber familiarity and product-specific dosing.

Oral Pharmacotherapy — Generalized or Segmental Dystonia, or Botulinum Toxin-Inadequate Focal Disease

Second-line to botulinum toxin for focal/segmental dystonia; first-line oral options for generalized disease. Titrate to the lowest effective dose given the genuine anticholinergic/sedative burden of this class.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Trihexyphenidyl	Adults: Start low, titrate slowly to effect Children: Higher mg/kg doses generally tolerated; titrate slowly	Anticholinergic burden, cognitive/memory effects (especially in older adults), blurred vision, constipation	Additive anticholinergic burden with other anticholinergic drugs	High-dose therapy is far better tolerated in children with generalized dystonia than in adults.
Baclofen	Oral: Start low, titrate to effect Intrathecal: Specialist-programmed pump	Sedation, weakness, hypotonia; abrupt-withdrawal seizures/rebound spasticity	Additive CNS depression with other sedating drugs	Intrathecal delivery is an option for severe generalized dystonia, particularly of secondary/structural cause.
Diazepam	Adjunct: Individualized, low starting dose, titrate to effect	Sedation, dependence with prolonged use, tolerance	Additive CNS depression with other sedating drugs, including baclofen and anticholinergics	An adjunct alongside other agents, not primary monotherapy, for most dystonia phenotypes.

Tardive Dystonia — VMAT2 Inhibitors (NOT Anticholinergics)

Anticholinergics are not recommended here and may worsen tardive syndromes — this class, not the acute-reaction anticholinergics, is first-line. Tetrabenazine is the only Health Canada-approved, Canadian-available option in this class.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Tetrabenazine	Adults, initial: 12.5 mg PO twice or three times daily Titration: Increase by up to 12.5 mg/day at weekly intervals Usual maximum tolerated: About 25 mg three times daily (rare cases to 200 mg/day)	Sedation (most common dose-limiting effect), depression/suicidality, akathisia, parkinsonism, QT prolongation, hyperprolactinemia	Contraindicated with MAOIs and reserpine; strong CYP2D6 inhibitors substantially increase exposure; avoid with other QT-prolonging drugs	Contraindicated in hepatic impairment, active suicidality, and untreated depression. Start low and titrate slowly.
Valbenazine	U.S. labelling: 40-80 mg PO once daily	Sedation, akathisia, dose-dependent QT prolongation	Avoid with other QT-prolonging drugs; strong CYP3A4 inducers/inhibitors affect exposure	FDA-approved for tardive dyskinesia; not Health Canada-approved and not available in Canada — included for pharmacist recognition only.
Deutetrabenazine	U.S. labelling: Twice-daily dosing per product labelling	Sedation, akathisia, dose-dependent QT prolongation	Avoid with other QT-prolonging drugs; strong CYP2D6 inhibitors affect exposure	FDA-approved for tardive dyskinesia; not Health Canada-approved and not available in Canada — included for pharmacist recognition only.

Avoid in Tardive Dystonia — the Acute-Reaction Anticholinergics

Listed here specifically because these are the exact drugs used first-line for the acute dystonic reaction (see above) — the single most important contrast to hold onto in this chapter. Do not substitute one of these for a VMAT2 inhibitor in tardive dystonia.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Benztropine	Tardive dystonia: Avoid	Anticholinergic effects: dry mouth, blurred vision, urinary retention, confusion	Additive anticholinergic burden with other anticholinergic drugs	Not recommended for tardive dystonia/dyskinesia and may worsen tardive symptoms, despite being first-line for the acute dystonic reaction.
Diphenhydramine	Tardive dystonia: Avoid	Sedation, anticholinergic effects	Additive CNS depression with other sedating drugs	Same caution as benztropine — appropriate for the acute reaction, not for tardive dystonia.
Trihexyphenidyl	Tardive dystonia: Avoid	Anticholinergic burden, cognitive/memory effects, blurred vision, constipation	Additive anticholinergic burden with other anticholinergic drugs	Useful for generalized primary dystonia, but not for tardive dystonia specifically.

References

Phenomenology and classification of dystonia: a consensus update — Movement Disorders (Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VSC, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK). Mov Disord 2013;28(7):863-873
Dystonia — Canadian Movement Disorders Society. CMDS Patient Information, accessed 2026
Dystonic Reactions — StatPearls, StatPearls Publishing (Maheshwary A, Bhatti KS). StatPearls [Internet], updated February 22, 2026
VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review — CNS Spectrums (Patel AR, Hauser RA, Citrome L, et al.). CNS Spectrums 2025
Psychogenic Dystonia: A Review of 18 Cases — Canadian Journal of Neurological Sciences (Lang AE). Can J Neurol Sci 1995;22(2):136-143
NITOMAN (Tetrabenazine Tablets 25 mg) Product Monograph — Bausch Health, Canada Inc.. Date of Revision: October 1, 2020
CADTH Canadian Drug Expert Committee Recommendation: AbobotulinumtoxinA (Dysport Therapeutic — Ipsen Biopharmaceuticals Canada, Inc.) — CADTH Common Drug Review. CADTH Common Drug Review, July 2017
Clinical Review Report: AbobotulinumtoxinA (Dysport Therapeutic) — Summary of OnabotulinumtoxinA-Controlled Studies — CADTH Common Drug Review. CADTH Common Drug Review, 2017
Deep Brain Stimulation — Dystonia Medical Research Foundation Canada. DMRF Canada, About Dystonia: Treatments, accessed 2026
Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review — Tremor and Other Hyperkinetic Movements (Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K). Tremor Other Hyperkinet Mov 2024;14(1):13

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.